Literature DB >> 1371955

Structural properties of the glycoplasmanylinositol anchor phospholipid of the complement membrane attack complex inhibitor CD59.

W D Ratnoff1, J J Knez, G M Prince, H Okada, P J Lachmann, M E Medof.   

Abstract

CD59, the membrane regulator of autologous C5b-9 channel formation, exhibits variable sensitivity to cleavage by phosphatidylinositol-specific phospholipase C (PI-PLC), an enzyme that releases glyco-inositolphospholipid (GPI)-anchored proteins from cell surfaces. To determine whether the GPI-anchor phospholipid of CD59 is similar to that of decay-accelerating factor (DAF) and whether variation in its structure underlies its variable enzyme susceptibility, the GPI anchors of the two proteins expressed on erythrocytes, polymorphonuclear and mononuclear leucocytes were compared in situ and after purification. Flow cytometric analyses of PI-PLC-treated cells showed parallel cell type specific release of both proteins as a function of enzyme concentration. Non-denaturing PAGE analyses of alkaline/hydroxylamine-treated proteins (affinity-purified from [125I]-surface-labelled cells) provided evidence for (i) comparable proportions of GPI-anchor acylation, and (ii) alkali-resistant rather than alkali-sensitive lipid substituents in erythrocytes. These findings argue that the differential C5b-9 sensitivity that distinguishes paroxysmal nocturnal haemoglobinuria II and III erythrocytes does not derive from expression of CD59 molecules with alternative GPI-anchor phospholipid structures.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1371955      PMCID: PMC1554345          DOI: 10.1111/j.1365-2249.1992.tb03012.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  55 in total

1.  A human immunoglobulin G receptor exists in both polypeptide-anchored and phosphatidylinositol-glycan-anchored forms.

Authors:  B J Scallon; E Scigliano; V H Freedman; M C Miedel; Y C Pan; J C Unkeless; J P Kochan
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

2.  Variations in the red cells in paroxysmal nocturnal haemoglobinuria.

Authors:  W F Rosse
Journal:  Br J Haematol       Date:  1973-03       Impact factor: 6.998

3.  Inhibition of complement by a substance isolated from human erythrocytes. I. Extraction from human erythrocyte stromata.

Authors:  E M Hoffman
Journal:  Immunochemistry       Date:  1969-05

4.  Erythrocyte membrane inhibitor of reactive lysis: effects of phosphatidylinositol-specific phospholipase C on the isolated and cell-associated protein.

Authors:  M H Holguin; L A Wilcox; N J Bernshaw; W F Rosse; C J Parker
Journal:  Blood       Date:  1990-01-01       Impact factor: 22.113

5.  Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria.

Authors:  M H Holguin; L A Wilcox; N J Bernshaw; W F Rosse; C J Parker
Journal:  J Clin Invest       Date:  1989-11       Impact factor: 14.808

6.  Monoclonal antibodies capable of causing hemolysis of neuraminidase-treated human erythrocytes by homologous complement.

Authors:  N Okada; R Harada; T Fujita; H Okada
Journal:  J Immunol       Date:  1989-10-01       Impact factor: 5.422

7.  Complement lysis of human erythrocytes. Differeing susceptibility of two types of paroxysmal nocturnal hemoglobinuria cells to C5b-9.

Authors:  C H Packman; S I Rosenfeld; D E Jenkins; P A Thiem; J P Leddy
Journal:  J Clin Invest       Date:  1979-08       Impact factor: 14.808

8.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril.

Authors:  P J Fraker; J C Speck
Journal:  Biochem Biophys Res Commun       Date:  1978-02-28       Impact factor: 3.575

9.  Alternative membrane forms of Fc gamma RIII(CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions.

Authors:  J V Ravetch; B Perussia
Journal:  J Exp Med       Date:  1989-08-01       Impact factor: 14.307

10.  Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.

Authors:  M E Medof; T Kinoshita; V Nussenzweig
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

View more
  13 in total

1.  Comprehensive quantitative comparison of the membrane proteome, phosphoproteome, and sialiome of human embryonic and neural stem cells.

Authors:  Marcella Nunes Melo-Braga; Melanie Schulz; Qiuyue Liu; Andrzej Swistowski; Giuseppe Palmisano; Kasper Engholm-Keller; Lene Jakobsen; Xianmin Zeng; Martin Røssel Larsen
Journal:  Mol Cell Proteomics       Date:  2013-10-30       Impact factor: 5.911

Review 2.  Membrane defence against complement lysis: the structure and biological properties of CD59.

Authors:  A Davies; P J Lachmann
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

3.  Tears contain the complement regulator CD59 as well as decay-accelerating factor (DAF).

Authors:  E Cocuzzi; L B Szczotka; W G Brodbeck; D S Bardenstein; T Wei; M E Medof
Journal:  Clin Exp Immunol       Date:  2001-02       Impact factor: 4.330

Review 4.  Membrane proteins that protect against complement lysis.

Authors:  B P Morgan; S Meri
Journal:  Springer Semin Immunopathol       Date:  1994

5.  Expression of membrane anchored cytokines and B7-1 alters tumor microenvironment and induces protective antitumor immunity in a murine breast cancer model.

Authors:  Erica N Bozeman; Ashley Cimino-Mathews; Deepa K Machiah; Jaina M Patel; Arun Krishnamoorthy; Linda Tien; Rangaiah Shashidharamurthy; Periasamy Selvaraj
Journal:  Vaccine       Date:  2013-03-28       Impact factor: 3.641

6.  Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59.

Authors:  J Schmitz; J P Zimmer; B Kluxen; S Aries; M Bögel; I Gigli; H Schmitz
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

7.  Expression of the glycosylphosphatidylinositol-linked complement-inhibiting protein CD59 antigen in insect cells using a baculovirus vector.

Authors:  A Davies; B P Morgan
Journal:  Biochem J       Date:  1993-11-01       Impact factor: 3.857

8.  Mammalian glycophosphatidylinositol anchor transfer to proteins and posttransfer deacylation.

Authors:  R Chen; E I Walter; G Parker; J P Lapurga; J L Millan; Y Ikehara; S Udenfriend; M E Medof
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

9.  Sequence-specific 1H-NMR assignments and folding topology of human CD59.

Authors:  C M Fletcher; R A Harrison; P J Lachmann; D Neuhaus
Journal:  Protein Sci       Date:  1993-12       Impact factor: 6.725

10.  Functional activity of the membrane-associated complement inhibitor CD59 in a pig-to-human in vitro model for hyperacute xenograft rejection.

Authors:  B Heckl-Ostreicher; R Binder; M Kirschfink
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.